Original research Evaluation of exercise capacity with cardiopulmonary exercise testing and BNP levels in adult patients with single or systemic right ventricles

Abstract

IntroductionThe aim of the study was to evaluate exercise capacity using cardiopulmonary exercise test (CpET) and serum B-type natriuretic peptide (BNP) levels in patients with single or systemic right ventricles.Material and methodsThe study group included 40 patients (16 males) – 17 with transposition of the great arteries after Senning operation, 13 with corrected transposition of the great arteries and 10 with single ventricle after Fontan operation, aged 19–55 years (mean 28.8 ±9.5 years). The control group included 22 healthy individuals (10 males) aged 23–49 years (mean 30.6 ±6.1 years).ResultsThe majority of patients reported good exercise tolerance – accordingly 27 were classified in NYHA class I (67.5%), 12 (30%) in class II, and only 1 (0.5%) in class III. Cardiopulmonary exercise test revealed significantly lower exercise capacity in study patients than in control subjects. In the study vs. control group VO2max was 21.7 ±5.9 vs. 34.2 ±7.4 ml/kg/min (p = 0.00001), maximum heart rate at peak exercise (HRmax) 152.5 ±32.3 vs. 187.2 ±15.6 bpm (p = 0.00001), VE/VCO2 slope 34.8 ±7.1 vs. 25.7 ±3.2 (p = 0.00001), forced vital capacity (FVC) 3.7 ±0.9l vs. 4.6 ±0.3 (p = 0.03), forced expiratory volume in 1 s (FEV1) 3.0 ±0.7 vs. 3.7 ±0.9l (p = 0.0002) respectively. Serum BNP concentrations were higher in study patients than in control subjects; 71.8 ±74.4 vs. 10.7 ±8.1 (pg/ml) respectively (p = 0.00001). No significant correlations between BNP levels and CpET parameters were found.ConclusionsPatients with a morphological right ventricle serving the systemic circulation and those with common ventricle physiology after Fontan operation show markedly reduced exercise capacity. They are also characterized by higher serum BNP concentrations, which do not however correlate with CpET parameters.

State of the art papers Lipids, blood pressure, kidney – what was new in 2011?

“…Brain natriuretic peptide (BNP), a neurohormone synthesized in ventricular myocardium, is released into the circulation in response to ventricular dilatation and pressure overload [118, 119]. The plasma level of BNP is considered to be a powerful marker for cardiac dysfunction and a useful prognostic indicator in patients with critical CV diseases [120–122].…”

Experimentally modified Fontan circulation in an adolescent pig model without the use of cardiopulmonary bypass

“…The survival rates 5, 10 and 15 years after surgery have increased, and are 86%, 81% and 73%, respectively [7]. An important finding, from the socioeconomic aspect, is that many of those patients with a Fontan operation had, and continue to enjoy, a long and high quality of life [4,8]. …”

An update on biomarkers of heart failure in hypertensive patients

“…Increased antigen carbohydrate 125 level is associated with higher NYHA class and signs of fluid congestion [98,100,101]. Raised levels of glycoprotein CA125 has been shown to directly correlate with pulmonary artery wedge and right atrial pressures [88,89,102] and inversely correlates with the deceleration time of early filling on transmitral Doppler [89,90]. Núñez et al [90] found that a raised CA125 was associated with an increased 6-month mortality.…”

“…Biomarkers such as natriuretic peptides [43,86,87] and tumor marker antigen carbohydrate 125 (CA125) [88,89] have been suggested to be useful in determining the severity of disease and prognosis of clinical outcomes in patients with AHF [90].…”